A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in a method of therapy, wherein: R1is selected from: (i) phenyl, optionally substituted by R1aand R1b; (ii) pyridyl; and (iii) naphthyl, optionally substituted by one group R1c; R1a332323322, and -Br; R1bis -OH, and may only be present when R1ais -OH; R1c33; R2a3223322, and a group of formula (II), wherein R2b332323322, and -Br; wherein if R2ais H, then R1is pyridyl or bears a substituent; wherein if R1a22, R2ais not H; and if R2ais meta-dimethylamino, then R1 is not unsubstituted phenyl.
C07C 205/45 - Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly-bound oxygen atom, not being part of a —CHO group
C07C 225/22 - Compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly-bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
C07C 323/31 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
C07D 213/38 - Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
The disclosure provides BI-1 modulating peptides and methods for treating cancer in a subject by administering an effective amount of a BI-1 modulating peptide.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The disclosure provides BI-1 modulating peptides and methods for treating cancer in a subject by administering an effective amount of a BI-1 modulating peptide.
patents
